A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.
about
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A non-randomized, open-label, ...... tive, advanced gastric cancer.
@en
A non-randomized, open-label, ...... tive, advanced gastric cancer.
@nl
type
label
A non-randomized, open-label, ...... tive, advanced gastric cancer.
@en
A non-randomized, open-label, ...... tive, advanced gastric cancer.
@nl
prefLabel
A non-randomized, open-label, ...... tive, advanced gastric cancer.
@en
A non-randomized, open-label, ...... tive, advanced gastric cancer.
@nl
P2093
P2860
P1476
A non-randomized, open-label, ...... tive, advanced gastric cancer.
@en
P2093
Akihito Tsuji
Ayuko Yamamura
Daisuke Sakai
Do-Youn Oh
Hyun Cheol Chung
Kazunori Uenaka
Sameera R Wijayawardana
Se Hoon Park
Shigenori Kadowaki
Volker Wacheck
P2860
P2888
P304
P356
10.1007/S00280-017-3445-Z
P577
2017-10-25T00:00:00Z